E. Traver
Carlos III Health Institute
2 Papers
25 Citations
E. Traver is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Immunoglobulin E & Ovalbumin. The author has an hindex of 1, co-authored 1 publications. Previous affiliations of E. Traver include Autonomous University of Barcelona.
Chat about Author
Papers
Mucosal mast cells mediate motor response induced by chronic oral exposure to ovalbumin in the rat gastrointestinal tract
TL;DR: Ketotifen modified motor response in both OVA exposed and unexposed animals giving evidence of the importance of mast cells in intestine motor activity driving.
25
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial
Wolfgang Köhler,Marc Engelen,Florian Eichler,Robin H. Lachmann,Ali Fatemi,Jacinda B. Sampson,Ettore Salsano,Josep Gamez,Márk Molnár,Sílvia Pascual,Maria Rovira,Anna Vilà,Guillem Pina,Itziar Martin-Ugarte,Adriana Mantilla,Pilar Pizcueta,Laura Rodríguez-Pascau,E. Traver,Anna Vilalta,María Rosa Querol Pascual,Marco Martiniello,U. Meya,Fanny Mochel,Eavan Mc Govern,Elise Yazbeck,Magali Barbier,Marie-Pierre Luton,Françoise Pousset,Jean-Yves Hogrel,Isaac M. Adanyeguh,Florian Then Bergh,Caroline G. Bergner,A. Unterlauft,Hannes Roicke,Karl-Titus Hoffmann,C. Scherlach,A. Al Kalb,Bianca Meilick,Mandy Reuschel,S Fenu,Elena Mauro,Elaine Murphy,G Sivarama Krishna,Tiggy Beyene,Alba Sierra,Sara Quiñoa,Anna Belen Canovas,Zoltán Grosz,Báthori Györgyi,S. I. V. D. Stadt,Irene C. Huffnagel,Wouter J.C. Van Ballegoij,M. Voermans,Reza Seyedsadjadi,Camille Corre,N. Godbole,Natalie Grant,Claudia Maria Brito Pires,M. K. Trovato,Nancy Yeh,J. Robyn Goodman,Jennifer Keller,Chris Joseph,Keith Van Haren,Sarada Sakamuri,Tina Duong,Lila A Perrone,Stephanie Tran,Sally Dunaway Young,S. Hashmi +69 more
TL;DR: The finding that cerebral adrenoleukodystrophy, a life-threatening event for patients with adrenomyeloneuropathy, occurred only in patients in the placebo group supports further investigation of whether leriglitazone might slow the progression of cerebral adrenoleskystrophy.